NASDAQ:GRDX Entero Therapeutics (GRDX) Stock Price, News & Analysis $3.24 -0.21 (-5.94%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$3.26 +0.01 (+0.46%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC Filings About Entero Therapeutics Stock (NASDAQ:GRDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entero Therapeutics alerts:Sign Up Key Stats Today's Range$3.12▼$3.5650-Day Range$2.94▼$5.8452-Week Range$1.87▼$6.93Volume125,150 shsAverage Volume141,917 shsMarket Capitalization$23.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Entero Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its research has focused on therapies designed to act in the digestive tract, including candidates for celiac disease, inflammatory bowel disease and exocrine pancreatic insufficiency. Its pipeline has included latiglutenase, an oral enzyme therapy intended to break down gluten in the gut, and adrulipase, an oral enzyme replacement candidate for people with exocrine pancreatic insufficiency. These are investigational products and are not approved treatments. The company was formerly known as First Wave BioPharma before adopting the Entero Therapeutics name. Its work has centered on developing drug candidates rather than marketing approved medicines.AI Generated. May Contain Errors. Read More Entero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreGRDX MarketRank™: 1.330745772105 of 5 starsEntero Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 482nd out of 574 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Entero Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Entero Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entero Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntero Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.43% of the float of Entero Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntero Therapeutics has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entero Therapeutics has recently decreased by 69.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntero Therapeutics does not currently pay a dividend.Dividend GrowthEntero Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.34 News SentimentEntero Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Technology companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Entero Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Entero Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Entero Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.75% of the stock of Entero Therapeutics is held by insiders.Percentage Held by Institutions12.30% of the stock of Entero Therapeutics is held by institutions.Read more about Entero Therapeutics' insider trading history. Receive GRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRDX Stock News HeadlinesEntero Therapeutics (NASDAQ:GRDX) Upgraded to Hold at Wall Street ZenNovember 21 at 1:06 AM | americanbankingnews.comGridAI Technologies Signs Definitive Agreement to Acquire Pronghorn Resources, Establishing Major Wyoming Owned-Natural Gas and Multi-Gigawatt AI Power Infrastructure Platform Targeting Initial Power Delivery in 2027November 13, 2026 | globenewswire.comSee More Headlines GRDX Stock Analysis - Frequently Asked Questions How have GRDX shares performed this year? Entero Therapeutics' stock was trading at $2.91 on February 6, 2026. Since then, GRDX stock has increased by 11.5% and is now trading at $3.2450. How were Entero Therapeutics' earnings last quarter? Entero Therapeutics, Inc. (NASDAQ:GRDX) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.27) earnings per share (EPS) for the quarter. The firm earned $38.11 thousand during the quarter. How do I buy shares of Entero Therapeutics? Shares of GRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GRDX's financial health is in the Green zone, according to TradeSmith. GRDX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:GRDX CIK1604191 Webwww.grid-ai.com Phone(561) 589-7020FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.39 million Net MarginsN/A Pretax Margin-13,634.24% Return on Equity-47.34% Return on Assets-16.07% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual Sales$40 thousand Price / Sales578.42 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book0.44Miscellaneous Outstanding Shares7,130,000Free Float8,476,000Market Cap$23.14 million OptionableN/A Beta1.67 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:GRDX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.